Later, by recruiting a total of 10,142 participants with T2DM with high cardiovascular risk, the CANVAS trial6 further supported the renoprotective role of an SGLT2 inhibitor (canagliflozin) in T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.